Amgen and Vertex Pharmaceuticals released their latest financial earnings reports Thursday afternoon.

Amgen experienced slight topline growth, with total revenues increasing 1% to $6.6 billion, thanks to 3% growth in global product sales. Repatha, Prolia, Lumakras and Evenity all saw double-digit volume growth.

The company generated $1.7 billion of free cash flow for the quarter and revised its total revenue guidance to a range of $25.5 billion to $26.4 billion. 

“We are focused on delivering our long-term objectives by serving an ever-increasing number of patients around the world with our medicines,” Amgen CEO Robert Bradway said in a statement. “We are advancing our pipeline and look forward to important readouts over the next few months.”

Amgen released its earnings report the same day it announced it will purchase ChemoCentryx, a company focused on orally administered treatments for autoimmune diseases, inflammatory disorders and cancer, in a $3.7 billion cash deal. The acquisition is expected to be completed in Q4 2022, pending regulatory approvals. 

“The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos, a transformative, first-in-class treatment for ANCA-associated vasculitis,” Bradway said in a statement.

Beyond its financial performance, Amgen launched a four-part podcast series in late June.

Meanwhile, Vertex’s product revenue increased 22% to $2.2 billion in Q2. The company boosted its full-year product revenue guidance to between $8.6 billion and $8.8 billion.

Trikafta led the way with product revenue of $1.8 billion during the quarter, with the company’s net income ballooning to $810 million. Additionally, Vertex’s operating income topped $1.1 billion, following an operating loss of $38 million in Q2 2021.

At the end of the quarter, Vertex had $9.3 billion in cash, cash equivalents and marketable securities, representing a $1.7 billion increase compared to the end of 2021.

“With sustained and growing leadership in CF, programs in five disease areas now entering or progressing through late-stage clinical development and the next wave of innovation beginning to enter the clinic later this year, Vertex has reached a new inflection point,” Vertex CEO Dr. Reshma Kewalramani said in a statement. “As we reach more CF patients, we are poised to deliver significant, durable financial returns for years to come. In parallel, we are advancing a broad and deep clinical pipeline of potentially transformative medicines across multiple serious diseases, spanning small molecules, cell and genetic therapies.”

During the quarter, Vertex announced an agreement to buy ViaCyte in a $320 million cash deal as well as expansion plans in Boston.